AxoGen (NASDAQ:AXGN) Announces Earnings Results

AxoGen (NASDAQ:AXGN) issued its quarterly earnings data on Wednesday. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.08, FiscalAI reports. AxoGen had a negative return on equity of 7.18% and a negative net margin of 11.96%. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $73.45 million.

Here are the key takeaways from AxoGen’s conference call:

• Positive Sentiment: AxoGen reported third-quarter revenue of $75.8 million, up 26.2% year over year, with breast revenue increasing more than 60% and adjusted EBITDA rising 46% to $13.4 million. Management raised 2026 guidance to at least $290 million in revenue, including $7 million from BioCircuit, while maintaining expectations for at least 73% gross margin and positive free cash flow.
• Positive Sentiment: Commercial payer coverage for Avance reached approximately 96% of U.S. covered lives after Elevance removed its nerve-gap restriction and Aetna added coverage for certain upper-extremity repairs. The company said breast growth is supported by expanding account adoption, with roughly 485 active breast accounts and 590 active surgeons.
• Positive Sentiment: AxoGen completed its $200 million BioCircuit acquisition, adding NerveTape and access to direct nerve-repair procedures representing an estimated 40%–50% of transected nerve cases. Management expects the product to contribute to revenue growth and adjusted EBITDA margin in its first year, although integration and potential cannibalization risks remain.
• Negative Sentiment: Gross margin declined to 74.8% from 76.6% a year earlier and is expected to decrease sequentially in the fourth quarter as production shifts toward longer Avance grafts for breast procedures. The company also warned that BioCircuit purchase-accounting inventory adjustments could further pressure fourth-quarter and full-year gross margin, while higher amortization and administrative expenses are expected going forward.
• Positive Sentiment: AxoGen plans to begin prostate nerve-reconstruction market development in 2027 after treating more than 220 patients across 15 sites; among patients with at least six months of follow-up, surgeons reported better-than-expected erectile-function recovery in approximately 80% and pad-free urinary continence above expected levels in more than 95%. Prostate is not included in current guidance, but management views it as a potentially meaningful long-term growth driver.

AxoGen Trading Up 0.8%

NASDAQ:AXGN opened at $49.63 on Friday. The company has a market capitalization of $2.67 billion, a P/E ratio of -76.35 and a beta of 1.17. AxoGen has a 12 month low of $21.68 and a 12 month high of $52.91. The firm has a fifty day simple moving average of $42.80 and a 200-day simple moving average of $39.36. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Earnings beat and higher guidance: AxoGen reported third-quarter earnings of $0.21 per share, exceeding consensus estimates of $0.13-$0.14 and improving from $0.12 a year earlier. Revenue reached approximately $75.8 million, also ahead of expectations. Management raised its 2026 revenue outlook to $290 million, reinforcing expectations for continued growth. AxoGen Shares Gap Up After Earnings Beat AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Broad analyst optimism: Canaccord Genuity raised its target from $55 to $60 and kept a Buy rating. Truist increased its target from $53 to $60, while Wells Fargo lifted its target from $48 to $56 with an Overweight rating. HC Wainwright also raised its target from $53 to $56 and maintained a Buy rating. These revisions suggest analysts view the earnings performance and outlook as supporting additional upside. Truist Raises AxoGen Price Target
• Positive Sentiment: Strong investor interest: Trading activity included purchases of 9,886 AXGN call options, nearly 10 times the average daily volume, indicating heightened speculative and bullish interest following the results.
• Neutral Sentiment: Despite the earnings momentum, AxoGen remains unprofitable on a trailing basis, with a negative net margin and analysts forecasting a loss for the full fiscal year. The stock’s substantial advance toward its 52-week high may also leave it more sensitive to profit-taking.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AXGN shares. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Wednesday, August 26th. Truist Financial raised their price target on shares of AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday. Barclays lifted their price target on shares of AxoGen from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday. HC Wainwright raised their price objective on shares of AxoGen from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Wall Street Zen lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.92.

Insiders Place Their Bets

In other AxoGen news, Director Amy Wendell sold 13,353 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director owned 107,976 shares of the company’s stock, valued at $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director directly owned 10,650 shares in the company, valued at $529,305. This represents a 24.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,503 shares of company stock valued at $4,656,947 over the last quarter. Insiders own 2.44% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.